Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cholinergic Antagonists: Therapeutic Uses

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Altered hypothalamic metabolism in chronic cluster headache patients measured with <sup>1</sup>H-MRS at ultra-high magnetic field.

The journal of headache and pain·2026

Same author

Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort.

Cephalalgia : an international journal of headache·2026

Same author

Machine Diagnostics and Machine Phenotyping of Migraine: A HUNT Study.

Neurology·2026

Same author

The effects of angiotensin receptor blockers as prophylactic migraine treatment: A systematic review and meta-analysis.

Cephalalgia : an international journal of headache·2026

Same author

Correction: What's a migraine day? Towards a consensus definition for clinical care and research - a Delphi panel-based study.

The journal of headache and pain·2026

Same author

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.

Neurology·2026

Search research articles

Related Experiment Video

Updated: May 22, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

[Prophylactic medicines for migraine].

Lars Jacob Stovner¹, Erling Tronvik, Knut Hagen

¹Nasjonalt kompetansesenter for hodepine, Institutt for nevromedisin, Det medisinske fakultet, Norges teknisk-naturvitenskapelige universitet. lars.stovner@ntnu.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke

|May 23, 2012

Summary

This summary is machine-generated.

Migraine patients should try prophylactic medications with realistic expectations and proper assessment. General practitioners must understand treatment principles for effective migraine prevention.

More Related Videos

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

Published on: November 1, 2024

Related Experiment Videos

Last Updated: May 22, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

Published on: November 1, 2024

Area of Science:

Neurology
Pharmacology

Background:

Frequent and disabling migraine attacks necessitate prophylactic treatment.
General practitioners require guidance on indications and principles for migraine prophylaxis.

Purpose of the Study:

To outline the approach to testing prophylactic medications for migraine.
To list currently licensed prophylactic drugs for migraine in Norway.

Main Methods:

Emphasizes patient education on realistic expectations and headache diary use.
Recommends gradual dose increase and a two-month trial period for assessing efficacy.
Considers scientific evidence, side effects, contraindications, comorbidities, usability, and cost in drug selection.

Main Results:

Licensed prophylactic migraine drugs include specific antihypertensives, antiepileptics, an antidepressant, and botulinum toxin for chronic migraine.
Severely affected patients may need to trial at least three different medications sequentially.

Conclusions:

Prophylactic treatment is crucial for frequent, disabling migraines.
A structured approach to medication testing and selection is essential for optimal patient outcomes.